1,3-Butanediol as a therapeutic for salt-sensitive hypertension
- Detailed Technology Description
- Project ID: D2018-47 Background In many populations, salt intake is greater than the recommended 3.75 grams per day.Excess salt consumption can lead to cardiovascular, renal, and liver problems, including high blood pressure. Exercise can naturally decrease hypertension, but can be difficult for some patients to incorporate into their life. Current medications for treating salt-sensitive hypertension target multiple organs and are ineffective to resistant hypertension. Therefore, there is a need for a more effective therapeutic for hypertension. Invention DescriptionResearchers found that 1,3-Butanediol treatment lowered hypertension by increasing Betahydroxybutyrate (BHB) in a Th17 independent pathway, thereby blocking the Nlrp3 inflammasome. This also had the effect of decreasing kidney fibrosis and improving kidney function. In vivo studies demonstrated lower levels of renal Nlrp3, Casp1, IL1b, IL18, Lcn2, etc. in high-salt diet rats treated with 1,3-butanediol. Protein casts and macrophage infiltration was also significantly lowered in kidneys of treated animals. Also, urinary protein excretion was significantly lower in the treated animals. Applications- Treatment for salt-sensitive hypertension- Nutraceutical or food additive Advantages- Already used as a hypoglycemic agent and is approved by the FDA for human consumption - Betahydroxybutyrate (BHB) is a host metabolite, not a xenobiotic- Preclinical trials completed IP Status: Patent pending
- *Abstract
-
- *Principal Investigator
-
Name: Bina Joe, Distingished University Professor
Department: Physiology and Pharmacology
Name: Saroj Chakraborty, Graduate Student
Department: Physiology and Pharmacology
- Country/Region
- USA
For more information, please click Here
